FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction

1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | |
|--------------------------|----------------------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Expires: | December 31, 2014 | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response | 0.5 | | | | | | | |

| 1. Name and Address of Reporting Person* | | | 2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX] | 5. Relationship of Reporting Person(s) to Issuer | | | | |
|--|-------------------------|--|--|--|--|--|--|--|
| | (Last) (First) (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 05/30/2013 | (Check all applicable) X Director 10% Owner Officer (give (specify below) | | | | |
| (Street) | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |

| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | |
|--|--|---|-------------------------------------|---|------------|------------------|-----------|--|--|---|--|--|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transac Code (Instr. 8) | | | | | 5. Amount of Securities Beneficially Owned | 6. Ownership Form: Direct (D) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | Code | V | Amount | (A) or (D) | Price | Following Reported Transaction(s) (Instr. 3 and 4) | or Indirect (I) (Instr. 4) | (Instr. 4) | | |
| Common Stock | 05/30/2013 | | S ⁽¹⁾ | | 44,582 (2) | D | \$ 30 (3) | 916,262 | I | See Footnote (4) | | |
| Common Stock | 05/31/2013 | | S ⁽¹⁾ | | 9,935 (5) | D | \$ 30 | 906,327 | I | See Footnote (6) | | |
| Common Stock | | | | | | | | 22,746 | D | | | |

| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|---|--|--|---|-------------------------------------|-------------------------------|-----|----------------------------|---------------------|--|-------|---|--|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transac Code (Instr. 8) | 5. Number of Derivative | | 6. Date Exercisable and | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

- 1. This transaction was pursuant to a 10b5-1 Plan.
- 2. The shares were sold as follows: 41,782 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 1,610 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 1,190 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC.
- 3. Represents the average sales price. The shares were sold between \$30.00 and \$30.01. The Reporting Person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 4. The shares are held as follows: 858,798 by BV IV QP, 33,089 by BV IV KG and 24,375 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- 5. The shares were sold as follows: 9,311 by BV IV QP, 359 by BV IV KG and 265 by AM BV4.
- 6. The shares are held as follows: 849,487 by BV IV QP, 32,730 by BV IV KG and 24,110 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

/s/ Luke Evnin 06/03/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.